Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2004



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Rational Design of Vaccines and Immunotherapeutics (A2)


Organizer(s) Margaret A. Liu and Peter C. Doherty
January 6—11, 2004
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Sep 15, 2003
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 6, 2003

Supported by Keystone Symposia


Summary of Meeting:
The past 2 decades have seen incredible advances in the fields of immunology and molecular biology. Simultaneously, remarkable novel technologies have provided new discovery tools for understanding pathogens and pathophysiology as well as for designing new delivery systems for vaccines and pharmacologic agents. Taken all together, these insights and developments have radically transformed the options for infectious and autoimmune diseases, cancer, and allergy by enabling new targets, new delivery systems, and new types of biologicals. These new agents have the potential to be both more specifically targeted and more precise mechanistically for increased potency and to avoid adverse effects. But to date, and for a variety of reasons, there has been less synergy of all these advances than needed to yield optimal progress towards real breakthrough vaccines and immunotherapies. There is a need for a non-commercial forum that will bring together scientists from the variety of disciplines, from industry as well as academia, and from the different stages of research and development. This meeting will enable scientists from different disciplines and technological backgrounds focusing on various immunological and developmental aspects of vaccines and immunotherapeutics to advance their knowledge in these inter-related areas outside of their own specialties and will provide the opportunity for cross-fertilization and interdisciplinary collaborations. A Keystone Symposium provides an ideal environment for a comprehensive and interactive meeting. The talks are designed to cover critical recent insights that are broadly applicable, while the workshops will enable in-depth coverage of specific topics. Because new technologies and discoveries can be presented in a workshop format, this will enable maximum opportunities for catalysis in order to most rapidly benefit from these diverse insights and developments to develop new ways to harness or control the immune response to prevent or treat the variety of diseases for which the immune system plays a pathological or beneficial role.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, JANUARY 6

15:00—19:00
Registration

Longs Foyer
18:15—19:15
Refreshments

Longs Foyer
19:15—19:30
Orientation

Grays Peak 1-3
19:30—21:30
Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-3
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Julie L. Gerberding, Merck & Co., USA
Preparing for 'The New Normal': Innovations in Countermeasures to Combat Public Health Threats

* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

Stanley A. Plotkin, Vaxconsult, LLC, USA
Rational Design of Vaccines: Revolution or Evolution?


WEDNESDAY, JANUARY 7

07:00—08:00
Breakfast

Longs Peak
08:00—11:00
T Cell Differentiation and Memory; Pathways of Antigen Processing, Co-Stimulation. Session Sponsored in Part by BD Technologies.
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
* Peter C. Doherty, University of Melbourne, Australia
Naïve and Memory T Cells in Viral Infections

Susan M. Kaech, The Salk Institute, USA
Pathways of Memory CD8 T Cell Differentiation

Susan L. Swain, University of Massachusetts Medical School, USA
Regulation of CD4 T Cell Memory Generation

Jay A. Berzofsky, NCI, NIH, USA
Role of IL-15 in CD8+ T Cell Memory and Avidity Maturation

08:00—11:00
Infectious Clone Technology: What Have We Learned So Far?
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* Michael J. Buchmeier, University of California Irvine, USA

Yoshihiro Kawaoka, University of Wisconsin/University of Tokyo, USA
The Power of Reverse Genetics

Adolfo García-Sastre, Mount Sinai School of Medicine, USA
Type I Interferon Antagonists of RNA Viruses: Novel Targets for Attenuation in Live Virus Vaccines

Juan Carlos de la Torre, The Scripps Research Institute, USA
Arenavirus Reverse Genetics: Implications for Novel Antiviral Strategies

Ute Stroeher, Canadian Science Centre for Human and Animal Health, Canada
Reverse Genetics Systems for High-Containment Viruses: Development and Potential Use

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Longs Peak
13:00—22:00
Poster Viewing

Longs Peak
14:00—16:00
Workshop 1: Skin and Mucosal Delivery of Vaccines

Grays Peak 1-2
* John A. Mikszta, BD Technologies, USA

* Peter Daddona, Zosano Pharma , Inc., USA

Catharine M. Bosio, NIAID, National Institutes of Health, USA
Immunogenicity and Protective Efficacy of Liposome-Based Mucosal Vaccines Against Y. pestis

Sophie Chabot, , USA
A Novel Intranasal Proteosome-Based Measles Vaccine Induces Neutralizing Antibody Responses in Mice

Lakshmi Krishnan, Institute for Biological Sciences, Canada
Delivery of Antigen in Archaeosome Adjuvant Sustains Antigen Presentation and CD8+ CTL Memory in vivo

Thomas M. Luby, Abraxis BioScience, USA
Generation of Immune Responses by Immunization with Plasmid DNA Encapsulated in Poly (Lactide-Co-Glycolide) Microparticles is Enhanced by in vivo Electroporation

Robert G. Ulrich, Research Institute of Infectious Diseases, USA
Evaluation of New Delivery Devices Targeting the Skin with Recombinant Protein Vaccines

Sarah M. Hook, University of Otago, New Zealand
A Formulation Approach to Improving Vaccine Innunogenicity

James Matriano, ALZA Corporation, USA
A Rapid and Efficient Skin Patch Technology for Vaccine Delivery

14:00—16:00
Workshop 1: Pathogen Receptor Interactions

Grays Peak 3
* Paul F. Bates, University of Pennsylvania School of Medicine, USA

Andrea F. Bertolotti-Ciarlet, University of Pennsylvania, USA
Cellular Processing and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus Glycoproteins

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Use of alpha-Dystroglycan as a Receptor by the Arenaviruses

David M. Koelle, University of Washington, USA
Intradermal Vaccinia and Skin-Homing T-Cells

Mansour Mohamadzadeh, Tulane Medical School, USA
Targeting HCV NS3-NS4A to Dendritic Cells (DC) via DC-Binding Peptides Induces Potent T Cell Immunity in vivo

Onesmo Mpanju, U.S. Food and Drug Administration, USA
Identification of Critical Amino Acid Residues on Ebola Virus Glycoprotein Required for Cell Entry

Ted C. Pierson, NIAID, National Institutes of Health, USA
Development of Novel Reporter Viruses for the Study of West Nile Virus Entry and its Inhibition

Christopher Premanandan, Ohio State University College of Veterinary Medicine, USA
Interactions of Bacillus anthracis Exotoxins and Cellular Receptors within the Phagolysosome

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—18:15
Genomics and Proteomics: Discovery of Antigens and Immune Modulators (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

Peter Andersen, Statens Serum Institut, Denmark
Post genomic insights for the design of TB vaccines for pre- and post-infection administration

Daniel J. Carucci, Foundation for the National Institutes of Health, USA
Identification of Malaria Vaccine Antigens by Proteomics and Incorporation into Molecular Vaccine Development

18:15—19:30
Genomic Responses to Infection (Joint)
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Alan Aderem, Center for Infectious Disease Research, USA
Large Scale Approaches to Dissecting the Innate Immune Response

David A. Relman, Stanford University, USA
How the Host Classifies Systemic Infection

19:30—20:30
Social Hour

Longs Peak
19:30—22:00
Poster Session 1

Longs Peak

THURSDAY, JANUARY 8

07:00—08:00
Breakfast

Longs Peak
08:00—11:00
Regulating Immune Responses: New Insights into T Helper Cells
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
Kevin J. Maloy, University of Oxford, UK
Control of Intestinal Inflammation by Regulatory T Cells

Jeffrey A. Bluestone, University of California, San Francisco, USA
Pathways to Tolerance in Autoimmunity

* Robert A. Seder, NIAID, National Institutes of Health, USA
Distinct Lineages of Th1 Memory Cells have Differential Survival in vivo: Implications for Vaccine Development Against Diseases Requiring Th1 Responses

Ronald N. Germain, NIAID, National Institutes of Health, USA
Self-Recognition and the Foreign Antigen Sensitivity of Naïve T Cells

08:00—11:00
New Information on Antiviral Mechanism of Action
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* Robert M. Krug, University of Texas at Austin, USA

Raul Andino, University of California, San Francisco, USA
The Fine Line Between Genetic Plasticity and Mutagenesis

Erik De Clercq, Katholieke Universiteit Leuven, Belgium
Therapeutic Potential of Nucleoside/Nucleotide Analogs Against Poxvirus Infections

Marc S. Collett, Viropharma, Inc., USA
Antiviral Drugs for Virological Threats of Bioterrorism and Emerging Diseases

Karl Y. Hostetler, University of California, San Diego, USA
Synthesis and Evaluation of Orally Active Drugs for Orthopoxvirus Infections

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Longs Peak
13:00—22:00
Poster Viewing

Longs Peak
14:00—16:00
Workshop 2: Vaccines for Developing Countries: Diseases and Technologies

Grays Peak 1-2
Martin Friede, World Health Organization, Switzerland
Aerosol Delivery of Vaccines: The Measles Aerosol Project

Yukio Koide, Hamamatsu University School of Medicine, Japan
Induction of Protective Cellular Immunity Against Mycobacterium tuberculosis by Recombinant Attenuated Self-Destructing Listeria monocytogenes Strains Harboring Eukaryotic Expression Plasmids for Ag85 complex and MPB/MPT51

Sandra Verhaagh, Crucell Holland BV, Netherlands
Studies Towards an Adenovirus-Based Malaria Vaccine

Carmel B. Stober, University of Cambridge, UK
From Genomes to Vaccines for leishmaniasis

Erik Rollman, BioArctic, Sweden
HPV-16 L1 Genes with Inactivated Negative RNA Elements Induce Potent Immune Responses

Maria J. Gonzalez, The Scripps Research Institute, USA
Induction of T-Cell Immunity by a Plant Virus Vaccine

Martin Friede, World Health Organization, Switzerland
Vaccines and Technologies for Resource-Poor Settings

14:00—16:00
Workshop 2: Novel Approaches to Therapeutics

Grays Peak 3
* Colleen B. Jonsson, University of Louisville, USA

Robert M. Krug, University of Texas at Austin, USA
Special Lecture: Novel Targets for Antivirals: The Multiple Functional Domains of the NS1 Proteins of Human Influenza Viruses

Jeffrey B. Arterburn, New Mexico State University, USA
New Synthetic Nucleoside Antivirals for Hantavirus

Frank Alexander Hamill, S.W. Foundation Biomedical Research, USA
Anti-Ebola, Anti-Lassa and Anti-SARS CoV Activity of Antimicrobial Natural Product Chemicals from Rubus apetalus

Lisa E. Hensley, NIAID, National Institutes of Health, USA
Evaluation of Interferon-beta as a Therapeutic Treatment for Ebola Hemorrhagic Fever in Nonhuman Primates

Benjamin W. Neuman, The Scripps Research Institute, USA
Arenavirus Inside Out: Cryo-EM Structural Studies of Three Arenaviruses

Tibor P. Keler, Celldex Therapeutics, Inc., USA
Development of Fully Human Antibody Against Anthrax Protective Antigen

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Innate Immunity: How to Harness or Suppress It
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
* Eyal Raz, University of California, San Diego, USA

Peter Aaby, Statens Serum Institut, Denmark
Non-Targeted Effects of Vaccination: Immune Effects and Impact on Additionally Administered Vaccines

Dennis M. Klinman, U.S. Food and Drug Administration, USA
Progress Towards Understanding the Properties of DNA

Heather L. Davis, Pfizer Inc., Canada
Use of CpG TLR9 Agonist as a Vaccine Adjuvant by Parental or Mucosal Routes

17:00—19:00
Impact of Receptor Binding
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* John A. T. Young, F.Hoffmann-La Roche Ltd, Switzerland
Anthrax Toxin-Receptor Interactions

Paul F. Bates, University of Pennsylvania School of Medicine, USA
Interaction of Ebola Virus Glycoproteins with Host Factors

Kathryn V. Holmes, University of Colorado School of Medicine, USA
Determinants of Coronavirus Host Ranges

19:00—20:00
Social Hour

Longs Peak
19:30—22:00
Poster Session 2

Longs Peak

FRIDAY, JANUARY 9

07:00—08:00
Breakfast

Longs Peak
08:00—11:00
Delivery Systems and Mucosal Immunization
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
Kam W. Leong, Johns Hopkins University in Singapore, Singapore
Formulation and Delivery Aspects of DNA Vaccination

Charles J. Arntzen, Biodesign Institute, Arizona State University, USA
Plant-Derived, Heat-Stable Subunit Vaccines for Oral Immunization

Jean-Marc Balloul, Transgene S.A., France
Antigen + Cytokine Immunotherapy for HPV-Induced Cervical Cancer

Thomas Lehner, Guy's, King's & St. Thomas' Hospital Medical and Dental School, UK
Innate and Adaptive Mucosal Immunity in Protection Against HIV Infection

08:00—11:00
SARS: The First Year
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* Peter B. Jahrling, National Institutes of Health, USA

Frank Plummer, Public Health Agency of Canada, Canada
SARS: Lessons Learned in Canada

Ralph S. Baric, University of North Carolina at Chapel Hill, USA
Reverse Genetics with a Full-Length Infectious cDNA of the Severe Acute Respiratory Disease Syndrome Coronavirus

Thomas G. Ksiazek, Centers for Disease Control, USA
Identification of a New Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)

Mark R. Denison, Vanderbilt University Medical Center, USA
SARS Coronavirus Genetics and Replication

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Longs Peak
13:00—22:00
Poster Viewing

Longs Peak
14:00—16:00
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Target Dendritic Cells

Grays Peak 1-2
* Liisa K. Selin, University of Massachusetts Medical School, USA
The Significance of Heterologous Immunity for Mixed Modality Vaccines

Claire L. Hutchings, University of Oxford, UK
Novel Immunization Strategies using DNA, Poxvirus and Protein Demonstrate a Widely Applicable Method for Simultaneous Induction of Potent Cellular and Humoral Immunity to the Co-Administered Protein and Encoded Antigen

Anne C. Moore, University of Oxford, UK
Pre-Existing Fowlpox Immunity is Less Inhibitory to Heterologous Prime-Boost Vaccine Strategies Compared to Anti-MVA Immunity

Andreas Mörner, Public Health Agency of Sweden, Sweden
Immunogenicity and Protective Efficacy of Three Different Prime-Boost HIV-1/SIV Vaccine Regimens in Macaques

John Stambas, St. Jude Children's Research Hospital, USA
Robust and Long-Lived Anti-HIV Envelope Responses Following a Prime-Boost-Boost Immunization Strategy

Markus Cornberg†, University of Massachusetts Medical School, USA
Private Specificity of Epitope Specific TCR Repertoire may Determine Patterns of Cross-Reactive T-Cell Responses

Chien-Fu Hung, Johns Hopkins University, USA
Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life with Intracellular Targeting Strategies

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Design of Vaccines that Regulate Dendritic Cell State and Trafficking

14:00—16:00
Workshop 3: SARS

Grays Peak 3
* Jean L. Patterson, Southwest Foundation for Biomedical Research, USA

Michael J. Buchmeier, University of California Irvine, USA
Antisense Morpholino Oligomers Directed Against the 5’-End of the Genome Inhibit SARS Coronavirus Proliferation and Growth

Dimiter S. Dimitrov, National Institutes of Health, USA
Cloning, Expression, Purification and Characterization of Full-Length and Soluble Fragments of the SARS-CoV S Glycoprotein

Kurt I. Kamrud, Synthetic Genomics Vaccines, Inc, USA
Development of an Alphavirus Replicon Vector Vaccine for SARS-CoV

Mark J. Cameron, Toronto General Hospital, Canada
Immune Responses in Patients with Severe Acute Respiratory Syndrome (SARS): Lessons from Cytokine and Gene Expression Profiling, FACS Analysis, and Epitope Mapping

Alessandro Sette, La Jolla Institute for Allergy & Immunology, USA
Human T-Cell Epitopes in SARS

Graham Simmons, University of Pennsylvania, USA
Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Encoded Spike (S) Glycoprotein Mediates Viral Entry

Jan terMeulen, Immune Design, USA
Mapping of Human B-Cell Epitopes on all Predicted Transmembrane Proteins of the SARS-CoV and Generation of Human Monoclonal Antibodies Against the Virus

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Technologies for APC Targeting, Stimulating Specific Arms of the Immune System
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
Melissa J. Robbiani (Pope), Population Council, USA
Exploiting Dendritic Cells for Improved Vaccines

* Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Targeting Different Antigen Processing Pathways for Biased Immune Responses

Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

17:00—19:00
Immune Therapy and Immunopotentiation of Disease
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* Kathryn V. Holmes, University of Colorado School of Medicine, USA

James D. Marks, University of California, San Francisco, USA
Recombinant Antibodies for Botulinum Neurotoxin Immunotherapy

Arturo Casadevall, Albert Einstein College of Medicine, USA
Immediate Immunity for Biological Defense - The Passive Antibody Option

Brent L. Iverson, University of Texas at Austin, USA
New Approaches to Antibody Engineering: An Improved Anti-PA Antibody

19:00—20:00
Social Hour

Longs Peak
19:30—22:00
Poster Session 3

Longs Peak

SATURDAY, JANUARY 10

07:30—08:30
Breakfast

Longs Peak
08:30—11:00
Lessons Learned from Diseases Requiring Stimulation of Immunity (Cancer, Preventive Vaccines)
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
David B. Weiner, Wistar Institute, USA
Engineering Improved DNA Vaccine Immune Responses

* Nicholas P. Restifo, NCI, National Institutes of Health, USA
How Lymphodepletion Enhances Autoimmunity and Cancer Regression after the Adoptive Transfer of T Cells

John D. Clemens, International Vaccine Institute, South Korea
Thinking Downstream to Accelerate the Introduction of New Vaccines for Developing Countries: The Importance of Translational Research

08:30—11:00
siRNA and Gene Silencing
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* Arturo Casadevall, Albert Einstein College of Medicine, USA

Carol D. Blair, Colorado State University, USA
Exploiting RNAi to Develop Arbovirus Resistance in Mosquitoes

Charles E. Samuel, University of California, Santa Barbara, USA
Interferon Action, Double-Stranded RNA, and Gene Silencing by RNA Interference

Nancy J. Sullivan, Vaccine Research Center, National Institutes of Health, USA
Strategies to Inhibit Ebola Virus Infection

09:20—09:40
Coffee Break

Longs Foyer
14:00—16:00
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodefense and Emerging Diseases

Grays Peak 1-2
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Darrell R. Galloway, Naval Medical Research Center, USA
DNA Vaccination Against Anthrax - An Update

Manisha Gupta, Centers for Disease Control, USA
Perforin is Required for Protection against Ebola Virus Infection

Karl J. Ljungberg, Karolinska Institutet, Sweden
SARS Coronavirus Inhibited by siRNA

Michael T. Rock, Vanderbilt University Medical Center, USA
Characterization of Immune Responses after Smallpox Immunization

Alessandro Sette, La Jolla Institute for Allergy & Immunology, USA
Dominance in T Cell Responses to Smallpox Vaccination

Søren Buus, University of Copenhagen, Denmark
SARS CTL Vaccine Candidates; HLA Supertype-, Genome-Wide Scanning and Biochemical Validation

14:00—16:00
Workshop 4: Host Responses

Grays Peak 3
* Barry J. Beaty, Colorado State University, USA

Igor M. Belyakov, National Cancer Institute, National Institutes of Health, USA
Shared Modes of Protection against Poxvirus Infection by Attenuated and Conventional Smallpox Vaccine Viruses

Jason W. Botten, The Scripps Research Institute, USA
Identification of Human Cytotoxic T Lymphocyte Epitopes Present in Lassa Virus

Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
Long Term B Cell Memory in Humans after Smallpox Vaccination

Menzo J. E. Havenga, Crucell Holland BV, Netherlands
Immunogenicity of Prototype Adenovirus-Based Ebola Vaccines in the Absence and Presence of Pre-Existing Adenovirus Immunity

Malachy I. Okeke, University of Tromsø, Norway, Norway
Characterization of Recombinant Viruses Obtained by Co-Infection of BHK-21 Cells with a Live Vaccinia Virus Vectored Influenza Vaccine and a Naturally Occurring Cowpox Virus

Ted M. Ross, University of Georgia, USA
Using C3d to Enhance Immune Responses to Infectious Agents

Amy C. Shurtleff, SRI International, USA
Production and Evaluation of a DNA Vaccine Against Lassa Virus in a Guinea Pig Infection Model

Christina F. Spiropoulou, Centers for Disease Control, USA
Hantavirus Infection Stimulates the MAPK/ERK Signaling Pathway to Produce Proinflammatory Chemokines

16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Lessons Learned from Diseases Requiring Altering Immunity (Autoimmunity, Allergy)
Meeting has ended...abstracts no longer viewable online.

Grays Peak 1-2
* Lawrence Steinman, Stanford University, USA
Reverse Genomics: Protein Microarrays Guide Tolerizing DNA Vaccine Treatment of Autoimmune Diseases

Gabriel Nussbaum, Hebrew University of Jerusalem, Israel
HSP60 Peptide Treatment of Autoimmune Diabetes

Eyal Raz, University of California, San Diego, USA
Probiotics for Inflammatory Bowel Disease: Mystery Unfolding

17:00—19:00
Circumventing and Directing the Immune Respone with Genetic Engineering
Meeting has ended...abstracts no longer viewable online.

Grays Peak 3
* Charles E. Samuel, University of California, Santa Barbara, USA

Joel R. Haynes, LigoCyte Pharmaceuticals, Inc., USA
Genetic Adjuvants for DNA Vaccines

Christopher P. Locher, Maxygen, Inc., USA
Development of a Novel Vaccines using DNA Shuffling/Screening Strategies and Bacillus Spore Display

R. Mark L. Buller, St. Louis University, USA
IL-4 Enhancement of Poxvirus Lethality: Implications for Small Pox

19:00—20:00
Social Hour

Longs Peak
20:00—23:00
Entertainment

Longs Peak

SUNDAY, JANUARY 11

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 U13 AI60000-01




We gratefully acknowledge additional support for this conference from:


BD Technologies
Beckman Coulter Foundation, Inc.
Bill & Melinda Gates Foundation Coley Pharmaceutical Group, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676